Saltar al contenido
Merck

C1231

SAFC

Colesterol, derivado vegetal

SyntheChol®

Fabricación farmacéutica

Sinónimos:

Colesterol, Colesterol sintético, 3β-Hidroxi-5-colesteno, 5-Colesten-3β-ol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C27H46O
Número de CAS:
Peso molecular:
386.65
Beilstein/REAXYS Number:
1915888
EC Number:
MDL number:
UNSPSC Code:
12352211

biological source

synthetic

Quality Level

agency

JP
NF
Ph. Eur.

assay

≥98%

form

crystals

bp

360 °C (lit.)

mp

147-149 °C (lit.)

density

1.067 g/mL at 25 °C (lit.)

suitability

suitable for manufacturing use

shipped in

dry ice

storage temp.

−20°C (−15°C to −25°C)

SMILES string

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1

InChI key

HVYWMOMLDIMFJA-DPAQBDIFSA-N

Gene Information

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Componente principal de todas las membranas biológicas; ~ el 25 % de todos los lípidos cerebrales es colesterol.

Preparation Note

Se sintetiza a partir de material de origen no animal

Legal Information

SyntheChol is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Steven A Grover et al.
The lancet. Diabetes & endocrinology, 3(2), 114-122 (2014-12-09)
Despite the increased risk of cardiovascular disease and type 2 diabetes associated with excess bodyweight, development of a clinically meaningful metric for health professionals remains a challenge. We estimated the years of life lost and the life-years lost from diabetes
Bo Angelin et al.
Journal of internal medicine, 277(3), 331-342 (2014-04-24)
Liver-selective thyromimetic agents could provide a new approach for treating dyslipidaemia. We performed a multicentre, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eprotirome, a liver-selective thyroid hormone receptor agonist, in 98 patients with primary hypercholesterolaemia. After
Michael J Pencina et al.
The New England journal of medicine, 370(15), 1422-1431 (2014-03-22)
The 2013 guidelines of the American College of Cardiology and the American Heart Association (ACC-AHA) for the treatment of cholesterol expand the indications for statin therapy for the prevention of cardiovascular disease. Using data from the National Health and Nutrition
Peter Libby et al.
Immunity, 38(6), 1092-1104 (2013-07-03)
According to the traditional view, atherosclerosis results from a passive buildup of cholesterol in the artery wall. Yet, burgeoning evidence implicates inflammation and immune effector mechanisms in the pathogenesis of this disease. Both innate and adaptive immunity operate during atherogenesis
Matthew P Buman et al.
American journal of epidemiology, 179(3), 323-334 (2013-12-10)
Sleep and sedentary and active behaviors are linked to cardiovascular disease risk biomarkers, and across a 24-hour day, increasing time in 1 behavior requires decreasing time in another. We explored associations of reallocating time to sleep, sedentary behavior, or active

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico